

## Primo partners with ABX to bring PB01 closer to Taiwan's prostate cancer market

21 March 2025 | News

**To bring a vital diagnostic tool to Taiwan, offering a new level of precision in cancer care**



In response to the growing burden of prostate cancer in Taiwan, Primo Biotechnology has formed a strategic partnership with Germany-based ABX advanced biochemical compounds GmbH (ABX) to lay the groundwork for introducing PB01 to the Taiwanese market.

Data from Taiwan Cancer Registry indicate a steady increase in both, the incidence and mortality of prostate cancer, in recent years, underscoring the urgent demand for more accurate diagnostic tools.

Radelumin, an innovative diagnostic radiotracer tailored specifically for prostate cancer patients, has already gained approval in France and multiple European countries. Using advanced PET/CT imaging technology, Radelumin and its equivalent for the Taiwanese market, PB01, enable precise detection of Prostate Specific Membrane Antigen (PSMA) expression, helping physicians identify and monitor prostate cancer with exceptional accuracy.

Since its European debut in 2021, Radelumin has become a widely adopted tool for early detection, staging, and recurrence monitoring in high-risk prostate cancer cases. The partnership between ABX and Primo aims to bring this vital diagnostic tool to Taiwan, offering a new level of precision in cancer care.